Mérieux Equity Partners (“MxEP”) and IK Partners (“IK”) are pleased to announce that Mérieux Participations 3 and the IK Small Cap II Fund and have signed an agreement to sell their respective stakes in Mabtech AB (“Mabtech” or “the Company”), a Swedish biotechnology firm specialising in immune monitoring, to EQT. Financial terms of the contemplated transaction are not disclosed.
